ARCH Venture Fund XIII, L.P.
CIK: 0002006772
Transaction Breakdown
Open Market Buys (P)1 (100.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LYEL
Lyell Immunopharma, Inc.
10% Owner
Discretionary Trading P&L
Holdings
About ARCH Venture Fund XIII, L.P.
ARCH Venture Fund XIII, L.P. (SEC CIK 0002006772) files insider reports with the SEC as 10% Owner of Lyell Immunopharma, Inc. (LYEL).
Signal8 holds 2 ownership filings by ARCH Venture Fund XIII, L.P. (1 Form 3, 1 Form 4), filed between Jul 29, 2025 and Mar 9, 2026. Those filings report 1 transaction, the latest on Mar 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on ARCH Venture Fund XIII, L.P.'s filings is in CHICAGO, IL.
Recent filings by ARCH Venture Fund XIII, L.P.
- Mar 6, 2026: Open-market purchase of LYEL shares (Form 4, code P).
Other insiders filing for Lyell Immunopharma, Inc. (LYEL)
- Aguirre Jarrad Mattieu, Chief Medical Officer
- Shook David, Chief Medical Officer
- Seely Lynn, President and CEO
- Hill Stephen J., Chief Operating Officer
- Lee Gary K., Chief Scientific Officer
- Bulis Veronica Sanchez, VP, Corporate Controller